Axel Hoffmann,Heinrich Lannert,Klaus Brischwein,Frederic Christian Pipp,Juergen Reindl,Karin Groll,Michael Zuehlsdorf,Otmar Pfaff,Sabine Raab,Ulrike Dau,Benoit Destenaves
申请号：
US16258289
公开号：
US20190263913A1
申请日:
2019.01.25
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
